UBS Group Forecasts Strong Price Appreciation for Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health (NYSE:ELAN) had its price objective upped by stock analysts at UBS Group from $27.00 to $30.00 in a research note issued to investors on Thursday,MarketScreener reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price indicates a potential upside of 24.74% from the stock’s current price.

Several other equities analysts also recently weighed in on ELAN. Morgan Stanley boosted their target price on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, December 18th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Finally, Zacks Research cut Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $25.44.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $24.05 on Thursday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $25.29. The business’s 50-day moving average is $23.02 and its 200 day moving average is $20.31. The company has a market capitalization of $11.95 billion, a P/E ratio of 400.90, a P/E/G ratio of 3.38 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,500 shares of Elanco Animal Health stock in a transaction on Thursday, December 11th. The stock was bought at an average cost of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This represents a 3.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer directly owned 167,000 shares in the company, valued at $3,632,250. This trade represents a 15.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by company insiders.

Institutional Trading of Elanco Animal Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Elanco Animal Health during the first quarter worth $2,065,000. Goldman Sachs Group Inc. increased its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. Empowered Funds LLC increased its holdings in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after purchasing an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Elanco Animal Health by 8.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock valued at $169,000 after purchasing an additional 944 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.